The fifth co-cited reference (31) proved that applying pioglitazone as agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) can reduce the incidence of macrovascular events in patients with type 2 diabetes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.